Successful Combination of Sunitinib and Girentuximab in Two Renal Cell Carcinoma Animal Models: A Rationale for Combination Treatment of Patients with Advanced RCC

Anti-angiogenic treatment with tyrosine kinase inhibitors (TKI) has lead to an impressive increase in progression-free survival for patients with metastatic RCC (mRCC), but mRCC remains largely incurable. We combined sunitinib, targeting the endothelial cells with Girentuximab (monoclonal antibody c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neoplasia
Main Authors: Oosterwijk-Wakka, Jeannette C., de Weijert, Mirjam C.A., Franssen, Gerben M., Leenders, William P.J., van der Laak, Jeroen A.W.M., Boerman, Otto C., Mulders, Peter F.A., Oosterwijk, Egbert
Formato: Artigo
Idioma:Inglês
Publicado em: Neoplasia Press 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4351300/
https://ncbi.nlm.nih.gov/pubmed/25748241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neo.2014.12.011
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados